In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Tyler and Christina Bauman welcomed their daughter, Emersyn, into the world on Aug. 19, 2024, at Children’s Minnesota in St.

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...

Patients with IBD have a higher risk for interstitial lung disease than the general population, with the risk being more ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more ...

Legionnaires’ disease is a rare condition, and incidence is hard to estimate because diagnosis requires a suspicion of ...

For Hairston, the lack of urgency expressed not only by MSHA but also elected officials who he feels should prioritize miners ...